Patent · US Active

Medium system and method for ex vivo expansion of NK cells

US10450547B1 · kind B1 · utility

1Cited by

1References

15Claims

0Family size

Assignee

PURECELL BIOMEDICAL TECHNOLOGY COMPANY LIMITED · CN

Inventors

Zhenhua Sun · Suzhou, CN
Hui Cao · Shenyang, CN

Key dates

Filing date	Mar 6, 2019
Grant date	Oct 22, 2019
Priority date	—
Expiry date	Mar 6, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2501/599
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to a medium system and a method for ex vivo expansion of natural killer (NK) cells. This invention directly cultures Ficoll-separated PBMC by using immobilized anti-CD137 and RetroNectin, and uses OK-432 as a biological effector under the co-existence of GM-CSF, IL-4, IL-2, IL-15, and IL-21 for ex vivo activation and proliferation of NK cells, creating an efficient method for ex vivo expansion of NK cells. The expression rate of NK cells CD3-CD16+/CD56+ prepared by the method is as high as 92.5% or more. After 14 days of culture, NK cells can be expanded 1000 to 2000 times and have strong in vitro cytotoxic activity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.